193 related articles for article (PubMed ID: 25232677)
61. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
62. Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy.
He JH; Liao XL; Wang W; Li DD; Chen WD; Deng R; Yang D; Han ZP; Jiang JW; Zhu XF
Int J Oncol; 2014 Sep; 45(3):1099-108. PubMed ID: 24919770
[TBL] [Abstract][Full Text] [Related]
63. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
64. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
65. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
66. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
[TBL] [Abstract][Full Text] [Related]
67. SLUG is activated by nuclear factor kappa B and confers human alveolar epithelial A549 cells resistance to tumor necrosis factor-alpha-induced apoptosis.
Wang Y; Yue B; Yu X; Wang Z; Wang M
World J Surg Oncol; 2013 Jan; 11():12. PubMed ID: 23339680
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
69. Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL.
Konishi T; Sasaki S; Watanabe T; Kitayama J; Nagawa H
Oncogene; 2006 May; 25(22):3160-9. PubMed ID: 16407826
[TBL] [Abstract][Full Text] [Related]
70. Expression of ErbB2 enhances radiation-induced NF-kappaB activation.
Guo G; Wang T; Gao Q; Tamae D; Wong P; Chen T; Chen WC; Shively JE; Wong JY; Li JJ
Oncogene; 2004 Jan; 23(2):535-45. PubMed ID: 14724581
[TBL] [Abstract][Full Text] [Related]
71. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
[TBL] [Abstract][Full Text] [Related]
72. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract][Full Text] [Related]
73. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
74. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
[TBL] [Abstract][Full Text] [Related]
75. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
76. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
77. The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer.
Li YQ; Fan F; Wang YR; Li LY; Cao YJ; Gu SM; Liu SS; Zhang Y; Wang J; Tie L; Pan Y; Li HF; Li XJ
Biochem Pharmacol; 2023 Oct; 216():115807. PubMed ID: 37716621
[TBL] [Abstract][Full Text] [Related]
78. NF-κB activation fails to protect cells to TNFα-induced apoptosis in the absence of Bcl-xL, but not Mcl-1, Bcl-2 or Bcl-w.
Casanelles E; Gozzelino R; Marqués-Fernández F; Iglesias-Guimarais V; Garcia-Belinchón M; Sánchez-Osuna M; Solé C; Moubarak RS; Comella JX; Yuste VJ
Biochim Biophys Acta; 2013 May; 1833(5):1085-95. PubMed ID: 23369735
[TBL] [Abstract][Full Text] [Related]
79. TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change.
Payapilly A; Guilbert R; Descamps T; White G; Magee P; Zhou C; Kerr A; Simpson KL; Blackhall F; Dive C; Malliri A
Cell Rep; 2021 Nov; 37(6):109979. PubMed ID: 34758330
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
